Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases
Ali Mir1, Montaha Almudhry1, Fouad Al-Ghamdi1
1Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Insights
Epilepsia partialis continua (EPC) is a difficult-to-treat epilepsy. Perampanel successfully treated EPC in two pediatric patients with rare underlying conditions, offering a new therapeutic option.
Area of Science:
- Neurology
- Pediatric Neurology
- Epileptology
Background:
- Epilepsia partialis continua (EPC) is a severe form of focal motor status epilepticus.
- EPC presents diagnostic and therapeutic challenges, often proving drug-resistant.
- Current treatment guidelines for EPC are limited, necessitating exploration of novel therapies.
Observation:
- Two pediatric cases of EPC, one with neuronal ceroid lipofuscinosis (NCL) and another with POLG-related mitochondrial disease, were reported.
- Both patients exhibited persistent focal motor seizures refractory to multiple antiepileptic drugs (AEDs).
- Perampanel was initiated in both cases, leading to rapid cessation of EPC episodes.
Findings:
- Perampanel demonstrated rapid and sustained efficacy in resolving EPC in both pediatric patients.
- The treatment was well-tolerated, with significant improvement observed within three days of initiation.
- Both patients maintained seizure control for approximately five months post-treatment.
Implications:
- Perampanel represents a promising therapeutic option for drug-resistant EPC, particularly in pediatric cases with rare etiologies.
- The unique mechanism of action of perampanel warrants further investigation for EPC management.
- This case series contributes valuable evidence for the clinical utility of perampanel in challenging epilepsy syndromes.
Abstract:
Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus, associated with multiple etiologies. Etiology-specific treatments, such as hemispherotomy for Rasmussen encephalitis, lesionectomy for focal cortical dysplasia, and metabolic correction for non-ketotic hyperglycemia, have proven to be efficacious in treating EPC, but, in general, EPC is difficult to treat and often drug-resistant, and there is little evidence to guide therapy. We report the successful treatment of EPC with perampanel in two pediatric patients. The first patient was a 12-year-old boy with neuronal ceroid lipofuscinosis (NCL) who started to have EPC around the age of 10 years, characterized by left hemifacial myoclonic twitches and hemi-body jerks that were almost continuous throughout the day and disappeared during sleep. He had failed several antiepileptic drugs (AEDs). The EPC stopped within three days of initiating perampanel. The second patient was a six-year-old boy with POLG-related mitochondrial disease who presented to the emergency room with continuous jerky movements of the right arm and face after a trivial head injury. After failing several AEDs, including a midazolam drip, the EPC was controlled with perampanel. Both patients showed dramatic improvement and continue to show sustained efficacy after around five months of follow-up. Based on our observations, perampanel, which has a unique mechanism of action, appears to be a promising therapeutic option for treating EPC. [Published with video sequence].
More Related Videos
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy


